

## ATTACHMENT 5



**IOM Recommended CIRM establish a Scientific Advisory Board (SAB).** The IOM recommended CIRM should establish a Scientific Advisory Board comprising individuals with expertise in the scientific, clinical, ethical, industry and regulatory aspects of stem cell biology and cell-based therapies. A single Scientific Advisory Board, as opposed to multiple advisory boards as proposed in the 2012 strategic plan, would provide cohesive longitudinal and integrated advice to the president regarding strategic priorities, which is lacking in the current CIRM organizational structure. The majority of the members of the Scientific Advisory Board should be external to California, appointed by and reporting to the President. Such an external board would be invaluable in vetting ideas for new RFAs, suggesting RFAs that otherwise would not have been considered, and helping CIRM maintain an appropriate balance in its research portfolio. Input from this board would help CIRM make fundamental decisions about dealing with challenges that cut across particular diseases, decide which discoveries should progress toward the clinic, and determine how best to engage industry partners in developing therapies. The Scientific Advisory Board's reports and the President's response to those reports should be delivered to the ICOC and discussed in open session.

**Legal Assessment:** The President is already empowered to establish an SAB that can provide counsel on such issues as RFAs, funding priorities, portfolio strategy and other matters identified by senior management. No ICOC Board action is required to implement the IOM's recommendation.

**Response:** The President will establish a single SAB that will provide counsel on such issues as RFAs, funding priorities, portfolio strategy and other matters identified by senior management. The SAB will be separate and complementary to ad hoc panels and councils the Office of the President has the discretion to call upon and create.

**Scope of the SAB:** The SAB will engage with the President and key senior staff on critical and major strategic issues that will accelerate the impact and delivery of the CIRM mission. Areas of review and recommendation will include: focus of CIRM's science and translational programs to ensure leadership and delivery within the current funding timelines; development of CIRM partnerships that will align with future delivery of clinical outcomes; identification of new opportunities for CIRM in the field; identification of key areas that need funding and focus for CIRM; CIRM's international connections for amplifying CIRM's scientific and translational progress, and assessment of CIRM's

## ATTACHMENT 5

funding model and how it can be fortified and transferred to other states and countries. The topics for discussion will be mutually developed by the Office of the President and the SAB.

**Composition of the SAB:** The President will appoint the membership of the SAB and be responsible for their meetings and reports. The SAB will be composed of 6-8 members with 50% or more of the members external to California. The members will cumulatively represent expertise in the scientific, clinical, ethical, industry and regulatory aspects of stem cell biology and cell-based therapies. The SAB will exclude from consideration those individuals from institutions/companies that are CIRM grantees or loan recipients, and members of the SAB will abide by CIRM conflict of interest and confidentiality policies. The term of membership on the SAB will be 2 years, and there will be the opportunity for CIRM to reappoint the members for another 2 year term, if there is mutual interest in doing so. The President retains the ability to appoint new members in relevant expertise as deemed important to the scientific mission of CIRM, and to replace members who leave the SAB.

**Frequency of Meetings:** The discussions of the SAB will be held 2-4 times per year, with at least one in-person meeting.

**Reporting Relationship:** The SAB will report to the President. Recommendations by the SAB will be subject to key senior management review and commentary before being presented to the ICOC.